Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis

OBJECTIVE: To assess whether canakinumab, a monoclonal antibody against IL-1β approved for autoinflammatory diseases, is effective as target-specific therapy in patients with sporadic inclusion body myositis (sIBM). METHODS: Because in sIBM IL-1β colocalizes with amyloid precursor protein and upregu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmidis, Michalis L., Pikazis, Dimitris, Vlachoyiannopoulos, Panayotis, Tzioufas, Athanasios G., Dalakas, Marinos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624107/
https://www.ncbi.nlm.nih.gov/pubmed/31355317
http://dx.doi.org/10.1212/NXI.0000000000000581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624107/
https://www.ncbi.nlm.nih.gov/pubmed/31355317
http://dx.doi.org/10.1212/NXI.0000000000000581

Ejemplares similares